We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
China’s National Medical Products Administration has approved Innovent Biologics’ Humira biosimilar Sulinno (adalimumab injection) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis. Read More
The FDA has updated its guidance on the use of convalescent plasma to treat COVID-19 or in clinical trials of treatments to take account of the administration’s Aug. 23 Emergency Use Authorization (EUA). Read More
Democrats on the House Energy and Commerce committee urged HHS Secretary Alex Azar yesterday to protect the 340B Drug Pricing Program following threats from several drugmakers to end discounts to hospitals that they pass on to patients under the program. Read More
The FDA has ousted another high-ranking communications officer following fallout from FDA Commissioner Stephen Hahn’s misrepresentation of convalescent plasma as a COVID-19 treatment. Read More
Drugmakers are concerned that President Trump may expedite implementation of an executive order aimed at lowering drug prices by ordering HHS to issue an interim final rule ahead of the Nov. 3 presidential election. Read More
In observance of the Labor Day holiday, Drug Industry Daily will not be published Monday, Sept. 7. The next issue will be published Tuesday, Sept. 8. Read More